

List of references CM24:

1. Kim WM, Huang YH, Gandhi A, Blumberg RS. CEACAM1 structure and function in immunity and its therapeutic implications. *Semin Immunol*. 2019 Apr;42:101296. doi: 10.1016/j.smim.2019.101296. PMID: 31604530; PMCID: PMC6814268.
2. Horst AK, Ito WD, Dabelstein J, Schumacher U, Sander H, Turbide C, Brümmer J, Meinertz T, Beauchemin N, Wagener C. Carcinoembryonic antigen-related cell adhesion molecule 1 modulates vascular remodeling in vitro and in vivo. *J Clin Invest*. 2006 Jun;116(6):1596-605. doi: 10.1172/JCI24340. Epub 2006 May 4. PMID: 16680193; PMCID: PMC1448166.
3. Li Y, Shively JE. CEACAM1 regulates Fas-mediated apoptosis in Jurkat T-cells via its interaction with β -catenin. *Exp Cell Res*. 2013 May 1;319(8):1061-72. doi: 10.1016/j.yexcr.2013.02.020. Epub 2013 Mar 7. PMID: 23499736; PMCID: PMC3765085.
4. Rayes RF, Vourtzoumis P, Bou Rjeily M, Seth R, Bourdeau F, Giannias B, Berube J, Huang YH, Rousseau S, Camilleri-Broet S, Blumberg RS, Beauchemin N, Najmeh S, Cools-Lartigue J, Spicer JD, Ferri LE. Neutrophil Extracellular Trap-Associated CEACAM1 as a Putative Therapeutic Target to Prevent Metastatic Progression of Colon Carcinoma. *J Immunol*. 2020 Apr 15;204(8):2285-2294. doi: 10.4049/jimmunol.1900240. Epub 2020 Mar 13. PMID: 32169849; PMCID: PMC7534954.
5. Park DJ, Sung PS, Kim JH, Lee GW, Jang JW, Jung ES, Bae SH, Choi JY, Yoon SK. EpCAM-high liver cancer stem cells resist natural killer cell-mediated cytotoxicity by upregulating CEACAM1. *J Immunother Cancer*. 2020 Mar;8(1):e000301. doi: 10.1136/jitc-2019-000301. PMID: 32221015; PMCID: PMC7206970.
6. Gerstel D, Wegwitz F, Jannasch K, Ludewig P, Scheike K, Alves F, Beauchemin N, Deppert W, Wagener C, Horst AK. CEACAM1 creates a pro-angiogenic tumor microenvironment that supports tumor vessel maturation. *Oncogene*. 2011 Oct 13;30(41):4275-88. doi: 10.1038/onc.2011.146. Epub 2011 May 2. PMID: 21532628.
7. Suzuki S, Ogawa T, Sano R, Takahara T, Inukai D, Akira S, Tsuchida H, Yoshikawa K, Ueda R, Tsuzuki T. Immune-checkpoint molecules on regulatory T-cells as a potential therapeutic target in head and neck squamous cell cancers. *Cancer Sci*. 2020 Jun;111(6):1943-1957. doi: 10.1111/cas.14422. Epub 2020 May 19. PMID: 32304268; PMCID: PMC7293074.
8. Fantini M, David JM, Annunziata CM, Morelli MP, Arlen PM, Tsang KY. The Monoclonal Antibody NEO-201 Enhances Natural Killer Cell Cytotoxicity Against Tumor Cells Through Blockade of the Inhibitory CEACAM5/CEACAM1 Immune Checkpoint Pathway. *Cancer Biother Radiopharm*. 2020 Apr;35(3):190-198. doi: 10.1089/cbr.2019.3141. Epub 2020 Jan 13. PMID: 31928422; PMCID: PMC7360111.
9. Huang YH, Zhu C, Kondo Y, Anderson AC, Gandhi A, Russell A, Dougan SK, Petersen BS, Melum E, Pertel T, Clayton KL, Raab M, Chen Q, Beauchemin N, Yazaki PJ, Pyzik M, Ostrowski MA, Glickman JN, Rudd CE, Ploegh HL, Franke A, Petsko GA, Kuchroo VK, Blumberg RS. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. *Nature*. 2015 Jan 15;517(7534):386-90. doi: 10.1038/nature13848. Epub 2014 Oct 26. Erratum in: *Nature*. 2016 Aug 18;536(7616):359. PMID: 25363763; PMCID: PMC4297519.

10. Ortenberg R, Sapir Y, Raz L, Hershkovitz L, Ben Arav A, Sapoznik S, Barshack I, Avivi C, Berkun Y, Besser MJ, Ben-Moshe T, Schachter J, Markel G. Novel immunotherapy for malignant melanoma with a monoclonal antibody that blocks CEACAM1 homophilic interactions. *Mol Cancer Ther*. 2012 Jun;11(6):1300-10. doi: 10.1158/1535-7163.MCT-11-0526. Epub 2012 Mar 30. PMID: 22466331.
11. Acharya N, Sabatos-Peyton C, Anderson AC. Tim-3 finds its place in the cancer immunotherapy landscape. *J Immunother Cancer*. 2020 Jun;8(1):e000911. doi: 10.1136/jitc-2020-000911. PMID: 32601081; PMCID: PMC7326247.
12. Markel G, Seidman R, Stern N, Cohen-Sinai T, Izhaki O, Katz G, Besser M, Treves AJ, Blumberg RS, Loewenthal R, Mandelboim O, Orenstein A, Schachter J. Inhibition of human tumor-infiltrating lymphocyte effector functions by the homophilic carcinoembryonic cell adhesion molecule 1 interactions. *J Immunol*. 2006 Nov 1;177(9):6062-71. doi: 10.4049/jimmunol.177.9.6062. PMID: 17056532.
13. Markel G, Lieberman N, Katz G, Arnon TI, Lotem M, Drize O, Blumberg RS, Bar-Haim E, Mader R, Eisenbach L, Mandelboim O. CD66a interactions between human melanoma and NK cells: a novel class I MHC-independent inhibitory mechanism of cytotoxicity. *J Immunol*. 2002 Mar 15;168(6):2803-10. doi: 10.4049/jimmunol.168.6.2803. PMID: 11884449.
14. Markel G, Seidman R, Cohen Y, Besser MJ, Sinai TC, Treves AJ, Orenstein A, Berger R, Schachter J. Dynamic expression of protective CEACAM1 on melanoma cells during specific immune attack. *Immunology*. 2009 Feb;126(2):186-200. doi: 10.1111/j.1365-2567.2008.02888.x. Epub 2008 Jun 13. PMID: 18557789; PMCID: PMC2632681.
15. Markel G, Ortenberg R, Seidman R, Sapoznik S, Koren-Morag N, Besser MJ, Bar J, Shapira R, Kubi A, Nardini G, Tessone A, Treves AJ, Winkler E, Orenstein A, Schachter J. Systemic dysregulation of CEACAM1 in melanoma patients. *Cancer Immunol Immunother*. 2010 Feb;59(2):215-30. doi: 10.1007/s00262-009-0740-5. PMID: 19633846.